Clinical applications of pharmacogenetics in psychiatry

Psychopharmacology

Volumn 162, Issue 1, 2002, Pages 18-23

  Staddon, Susan ^a   Arranz, Maria J ^a   Mancama, Dalu ^a   Mata, I ^b   Kerwin, Robert W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Fundacion Argibide   (Spain)

Author keywords

Antipsychotic and antidepressant response; Metabolic polymorphisms; Pharmacogenetics; Receptor variants

Indexed keywords

CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ENZYME; HALOPERIDOL; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DESIGN; DRUG SAFETY; GENETICS; HUMAN; MOTOR DYSFUNCTION; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; GENETIC POLYMORPHISM; MENTAL DISEASE; METHODOLOGY;

HUMAN; MENTAL DISORDERS; PHARMACOGENETICS; POLYMORPHISM (GENETICS); PSYCHIATRY; HUMANS; POLYMORPHISM, GENETIC;

EID: 0035987320     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1084-4     Document Type: Review

References (58)

1. 2A receptor gene
2. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response
3. 2A receptors and clozapine response
4. Pharmacogenetic prediction of clozapine response
5. Response to olanzapine influenced by genes in neurotransmitter receptors
6. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
7. Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders
8. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
9. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response
10. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups
11. A pharmacogenomic approach to Alzheimer's disease
12. Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias
13. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos
14. Genetic polymorphism of CYP2D6 and CYP2C19 in
15. Genetic determinants of clozapine-induced agranulocytosis: Recent results of HLA subtyping in a non-Jewish Caucasian sample
16. Identification and functional characterization of eight CYP3A4 protein variants
17. Metabolism, parmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs
18. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
19. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population
20. 3 receptor gene in schizophrenia patients: Identification of the Ala38Thr polymorphism and suggested association between DRD3 haplotypes and schizophrenia
21. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method
22. 4 receptor 48-bp repeat polymorphisms: No association with response to antipsychotic treatment, but association with catatonic schizophrenia
23. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
24. The positive and negative syndrome scale (PANSS) for schizophrenia
25. Serotonin transporter gene polymorphism and antidepressant response
26. CYP2D6 and CYP2C19 genotype-based dose recommendations for antide-pressants: A first step towards subpopulation-specific dosages
27. Initial sequencing and analysis of the human genome
28. The dopamine D-3 receptor (DRD3) Ser(9) Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response
29. Allelic variation in the promoter region of the dopamine receptor gene and clozapine response
30. The histamine 1 and histamine 2 receptor genes - Candidates for schizophrenia and clozapine response
31. Association analysis of muscarinic acetylcholine receptor polymorphisms in clozapine treated schizophrenics
32. Pharmacogenomics: Unlocking the human genome for better drug therapy
33. The role of serotonin in antipsychotic drug action
34. The evolution of drug metabolism
35. Pharmacogenetics of classical and new antipsychotic drugs
36. 3 receptor and cytochrome P450 1A2 genes
37. Pharmacogenomics and diagnostics
38. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the anti-psychotic agent olanzapine
39. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
40. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene
41. 3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients
42. Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile
43. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
44. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility
45. 4 receptor subtypes and response to clozapine
46. 3 receptor gene and schizophrenia
47. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
48. 2C receptor gene
49. 3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
50. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: Antidepressants and antipsychotics and the cytochrome P450 system
51. Tumor necrosis factor constellation polymorphism and clozapin-induced agranulocytosis in two different ethnic groups
52. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
53. Drug extrapyramidal side-effects or not: Is there a dextromethorphan phenotype difference?
54. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility
55. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response
56. Serotonin-6 receptor variant (C267T) and clinical response to clozapine
57. HLA associations in clozapine-induced agranulocytosis